ZEVRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.73 USD | -0.63% |
|
-1.87% | -27.79% |
| May. 13 | Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call | |
| May. 08 | Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 28.34M | Sales 2025 * | 95.58M | Capitalization | 198M |
|---|---|---|---|---|---|
| Net income 2024 * | -68M | Net income 2025 * | -16M | EV / Sales 2024 * | 6.99 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.07 x |
| P/E ratio 2024 * |
-3.16
x | P/E ratio 2025 * |
-11.6
x | Employees | 67 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.29% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zevra Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.95% | ||
| 1 week | -1.87% | ||
| Current month | +3.28% | ||
| 1 month | +1.94% | ||
| 3 months | -31.05% | ||
| 6 months | +8.99% | ||
| Current year | -27.79% |
1 week
4.67
5.05
1 month
4.395.30
Current year
4.397.28
1 year
3.897.28
3 years
3.8915.70
5 years
1.9432.00
10 years
1.94418.40
| Managers | Title | Age | Since |
|---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 06-10-29 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 23-10-09 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 23-04-24 |
Tamara Favorito
CHM | Chairman | 65 | 21-08-17 |
Douglas Calder
BRD | Director/Board Member | 56 | 23-04-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.44% | 4 M€ | -5.15% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 4.73 | -0.63% | 143,551 |
| 24-05-16 | 4.76 | -1.24% | 177,234 |
| 24-05-15 | 4.82 | +0.42% | 157,679 |
| 24-05-14 | 4.8 | -1.84% | 191,945 |
| 24-05-13 | 4.89 | +1.45% | 355,323 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.73
USD
Average target price
19
USD
Spread / Average Target
+301.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.79% | 198M | |
| +10.23% | 8.96B | |
| -10.76% | 5.19B | |
| +51.58% | 4.77B | |
| +12.50% | 4.26B | |
| -20.70% | 2.37B | |
| +12.83% | 2.3B | |
| +19.51% | 2.17B | |
| -29.65% | 2.21B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- ZVRA Stock
